ACA
RLMD icon

American Capital Advisory’s Relmada Therapeutics RLMD Stock Holding History

American Capital Advisory’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.6K Hold
1,954
– – 0.01% 320
2025
Q4 		$9.44K Hold
1,954
– – ﹤0.01% 329
2025
Q3 		$3.93K Hold
1,954
– – ﹤0.01% 366
2025
Q2 		$1.17K Sell
1,954
-1,954
-50% -$1K ﹤0.01% 474
2025
Q1 		$1.06K Buy
3,908
+1,954
+100% +$648 ﹤0.01% 424
2024
Q4 		$1.02K Hold
1,954
– – ﹤0.01% 421
2024
Q3 		$6.33K Buy
1,954
+754
+63% +$2.44K ﹤0.01% 330
2024
Q2 		$4.97K Hold
1,200
– – ﹤0.01% 304
2024
Q1 		$2.71K Hold
1,200
– – ﹤0.01% 351
2023
Q4 		$4.97K Buy
+1,200
New +$3.55K ﹤0.01% 304

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $250M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $93.4B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return